Opinion|Videos|December 21, 2023
Key Takeaways from ASH 2023 in Leukemia and Lymphoma
Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in leukemia and lymphoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
FDA accepts updated tab-cel BLA for EBV+ PTLD after transplant, adding ALLELE data; PDUFA decision set for March 31, 2027.
Real-world German MINT data show mogamulizumab delivers durable responses, ~20-month PFS, manageable safety, and improved quality of life in MF and Sézary syndrome.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206
4
Durability of PFS and OS Benefit vs. Historical Control
5